TNFSF10 and lung cancer: Although ABT-737 is anticipated to primarily act via the mitochondrial pathway of apoptosis, it has also been reported to act through the extrinsic pathway, where it enhances TRAIL-mediated cytotoxicity in renal, prostate and lung cancer cells by upregulating TRAIL receptor, death receptor 542.